While the pandemic has changed the way we work, many will agree there’s no substitute for meeting people in person: whether this is making new connections or simply catching up with established contacts. CPhI will unite thousands of pharma suppliers and buyers under one roof in Milan, over three days of sourcing, connecting and doing business (November 9-11).
The event covers the full pharma supply chain and is divided up into product-specific zones for easy navigation: Find the downloadable floor plans for the event here.
Here's just a taste of some of the exhibitors who will be there in person in Milan: Find the full list of exhibitors here.
Petrovax Pharm: Booth 3J63
Petrovax Pharm, a Russian biopharmaceutical company, will present its own original pharmaceutical products and flagships of the product portfolio - the immunomodulator Polyoxidonium, the enzyme preparation Longidaza, the vaccine for the influenza prevention Grippol plus, and a scar revision cream Imoferaza, as well as generics and dietary supplements.
Petrovax Pharm is a leading Russian developer and manufacturer of medicines and vaccines with 25 years of success in the pharma market. The company holds more than 20 patents for molecules and pharmaceutical manufacturing technologies. The manufacturing unit is compliant with the Russian and international GMP standards. The company manufactures APIs and finished dosage forms.
The company is an established partner of Pfizer, Abbott and Boehringer Ingelheim: having a unique experience in transferring technologies for full-cycle manufacturing of finished dosage form of the most high-tech drugs in the world: 13-valent pneumococcal vaccine Prevenar 13, innovative thrombolytics Actilyse and Metalyse. (Prevenar 13, which Petrovax Pharm manufactures and markets in partnership with Pfizer, is among the top 20 best-selling medicines in the world: and the volume of deliveries of Prevenar 13 vaccine to the Russian market has amounted to more than 35 million doses since 2014).
Petrovax is the largest Russian exporter of original medicines and vaccines; the products are exported to the countries of the EAEU, the Middle East, and the EU.
“The company's strategy is to continue geographical expansion and search for new international partners for cooperation in the following areas: vaccine prevention, biotechnological drugs and in-licensing molecules,” it explains. “Petrovax is open to business collaborations with international companies in the field of biotechnology. The company is ready to acquire, license, jointly develop drugs and invest in projects aimed at treating socially significant diseases in such areas as oncology and autoimmune disorders.”
W. R. Grace & Co: Booth 11F26
W. R. Grace & Co. will unveil a new pharmaceutical formulation solution, SYLOID XDP silica, at CPhI this year. SYLOID XDP silica is a patented, pharmaceutical-grade novel carrier that converts liquid, waxy, or oily active ingredients into free-flowing powders.
This processing innovation, which is produced using GMP, enables the conversion of liquid APIs into more convenient dosage forms: including hard capsules, tablets, stick packs, and sachets.
With a specially designed porous structure, this mesoporous synthetic silica-based processing aid absorbs 1 to 1.5 times its weight in liquid and remains a free flowing, non-dusty material. This solves several formulation challenges associated with liquid dosage forms, including issues of stability and bioavailability.
SYLOID XDP silica can also act as a substrate and enables the dry processing of self-emulsifying and self-micro emulsifying drug delivery systems. In addition, this patented technology enables manufacturers to achieve improved blend uniformity compared to traditional mixing methods. Handling and downstream processing are facilitated without any need for solvents or drying time.
The launch of SYLOID XDP silica follows the company’s June acquisition of the Fine Chemistry Services business, previously operated by Albemarle Corporation. Grace’s Fine Chemical Manufacturing Services (FCMS) extends the company’s pharmaceutical portfolio and it offers complementary expertise at three facilities from coast to coast to support the customized development of APIs, cGMP intermediates and RSMs.
In addition to showcasing its processing and purification technologies at CPhI, Grace will present a session on excipients as part of the event’s Learning Lab series.
Thermo Fisher Scientific: Booth 4G10
Thermo Fisher Scientific will showcase its newest capabilities across its global pharma services network which help pharmaceutical and emerging biotech companies accelerate time to market in a wide range of modalities and platforms including cell and gene therapies, drug products and biologics.
Biologics Development and Manufacturing: Thermo Fisher has recently assumed operational responsibility for a new 1.5-million-square-foot biologics manufacturing site in Lengnau, Switzerland as part of its strategic partnership with CSL Limited. In addition, the company has announced expansion of its 360,000-square-foot biologics manufacturing campus in St. Louis, Mo. with 58,000 square feet of manufacturing and production support at the 5KL processing scale and continued support at the 2KL processing scale.
Global Drug Product and Steriles Manufacturing Capabilities: The company has expanded its global steriles manufacturing commercial footprint with 12 new sterile commercial and development lines across four sites in the US and Europe which will be operational in 2021 and 2022. These expansions in Greenville, NC; Monza and Ferentino, IT; and Swindon, UK increase manufacturing capacity for sterile liquid and lyophilized filling, and pre-filled syringes.
Demand for Cell & Gene Therapy: The company opened its new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif., to support the production of commercial plasmid DNA used as a raw material or as a primary drug substance for gene-based therapies.
In viral vector services, Thermo Fisher broke ground on its new 290,000-square-foot manufacturing facility in Plainville, Mass., which will be one of the largest viral vector manufacturing facilities in North America when it opens in 2022. Through its acquisition of Henogen, Novasep's viral vector business, the company added more than 75,000 square feet of clinical and commercial manufacturing capacity with two locations in Seneffe and Gosselies, Belgium.
As part of its strategic collaboration with the University of California, San Francisco (UCSF), Thermo Fisher has begun construction on a state-of-the-art cell therapy development, manufacturing and collaboration center on UCSF's Mission Bay campus to advance cell therapy development and commercialization.
Growing Clinical Supply Chain Services: The company has opened two new state-of-the-art facilities in Germany. The Rheinfelden site delivers secondary packaging and storage and distribution of clinical supplies to investigator sites across Europe. In Weil am Rhein, a new cryocenter offers specialized ultra-low temperature, cryogenic storage and cold chain services.
Asia-Pacific Expansion: The company has begun construction on new facilities in Singapore and China, which will open in 2022. Its new facility in Singapore will include support for high-speed sterile fill-finish manufacturing. In Hangzhou, China, an integrated biologics and sterile drug development and manufacturing site will help bring novel therapies to market regionally and internationally.
Ajinomoto Bio-Pharma Services: Booth 4J10
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization, with sites in Belgium, US, Japan, and India; providing comprehensive process development services, cGMP manufacturing and drug product fill finish services of small molecule and large molecule APIs and intermediates.
The company will be at CPhI to explain its broad range of innovative platforms and capabilities to rapidly scale from clinical and pilot programs to commercial quantities.
Ajinomoto Bio-Pharma Services has announced a number of developments this year. It has created a high speed, multi-purpose fill finish line in its commercial manufacturing facility located in San Diego. The new fill line offers a range of configurations, including prefilled syringes, cartridges and vials, utilizing ready-to-use components, which minimize component preparation and packaging. Along with the line, the fill suite houses two formulation suites, one of which is capable of handling flammable compounds. The fully contained and integrated OPTIMA line uses SKAN isolated barrier technology to ensure the required sterility for fill finish, while offering flexibility to meet cGMP clinical and commercial drug product manufacturing needs. The high-speed process is rated to move 22,000 syringes per hour through the line, with a batch capacity of over 200 thousand syringes. In addition, it has been designed to meet FDA and EMEA commercial compliance.
In March, the company expanded its manufacturing agreement with AstraZeneca to include drug product manufacturing. In January, it expanded a manufacturing agreement with Humanigen for the fill finish supply of lenzilumab. And in March, it entered into a research collaboration and license agreement with Bright Peak Therapeutics on novel immunocytokines.
Logistics4Pharma: Booth 18H12
Logistics4Pharma, a pharmaceutical logistics and cold chain specialist, will be at CPhI having just announced several achievements.
The company recently completed GDP certification and ISO 9001:2015 quality management certifications for its Frankfurt, Germany cold chain storage and logistics facility. It also achieved the status of Authorised Economic Operator (AEO), which certifies the facility operates at the highest level of security and provide customers with customs simplification procedures.
These advances follow a recent completion of a successful inspection from German Authorities validating compliance with good distribution practice (GDP) regulations for the storage and transportation of active pharmaceutical ingredients (APIs) and finished drug products. Logistics4Pharma has also passed a recent audit from the Luftfahrt-Bundesamt (LBA) renewing Regulated Agent status under the supervision of the German Aviation Administration.
Logistics4Pharma a range for warehousing options (-15 to -25˚C, 2 to 8˚C and 15 to 25˚C), passive and active packaging solutions, transportation by air, land and sea, documentation, and customs clearance for active pharmaceutical ingredients (APIs), dangerous goods, and finished drug products. There are further plans to enhance the offer at the Frankfurt facility and include ultra-deep freeze capacity (-80˚C) in the coming year.
Syngene: Booth 4J43
This global CRO/CDMO offers integrated, end-to-end development and manufacturing services to advance clinical candidates from Preclinical all the way to NDA filing. Its high-end capabilities extend across Drug Products, Drug Substance, Commercial Manufacturing, Biologics, Analytical Development including ICH Stability studies, and Clinical Development.
Programs are supported by experienced project management teams who track the project’s overall progress in close coordination with the client to deliver products in line with client and regulatory expectations. The company boasts world-class infrastructure spread across 2 Mn sq. feet campus space.
“This year, we look forward to meeting clients/prospects at the physical event in Milan,” says the company. “Our experts will also be available virtually if required.”